Medical Condition News

RSS

Alnara to announce Phase 3 study results of liprotamase for treating cystic fibrosis at the 23rd NACFC

Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 study of the long-term safety and nutritional benefits of liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis (CF) will be presented at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) being held October 15-17, 2009 in Minneapolis, Minnesota.

5 Oct 2009

Supportive housing program is cost-effective option for people with mental illness

In the wake of a landmark decision by Federal District Judge Nicholas Garaufis, who in early September ruled that New York State is violating the Americans with Disabilities Act by segregating individuals with mental illness from the general population and fostering "learned helplessness," detrimental to rehabilitation and recovery, Community Access is inviting neighbors, local businesses and friends to tour its supportive housing sites in New York City this October

5 Oct 2009

VIVUS to present data on Qnexa at The Obesity Society meeting

VIVUS, Inc. today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.

5 Oct 2009

FDA grants Impax tentative approval of ANDA for FLOMAX generic version

Impax Laboratories, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company’s Abbreviated New Drug Application (ANDA) for generic version of FLOMAX® (tamsulosin hydrochloride) 0.4mg capsules. Boehringer Ingelheim Pharmaceuticals, Inc. markets FLOMAX® for the functional symptoms of benign prostatic hyperplasia.

5 Oct 2009

Positive results from Peregrine's Phase II bavituximab trial for non-small cell lung cancer

Peregrine Pharmaceuticals, Inc. today reported additional positive results in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). Data previously reported from the initial cohort of 21 patients in the study had indicated that 11 of 17 evaluable patients with locally advanced or metastatic NSCLC achieved an objective tumor response according to RECIST criteria.

5 Oct 2009

avVaa World Health Care Products launches Neuroskin Psoriasis Relief DRTV media test campaign

avVaa World Health Care Products Inc. a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced the launch of its two week Neuroskin(R) Psoriasis Relief DRTV media test campaign.

5 Oct 2009

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Seattle Genetics, Inc. announced today that it has discontinued the SeaGen MARINER clinical trial based on a determination that the trial would be unlikely to meet its primary endpoint of superior complete response rate in the dacetuzumab combination arm as compared to the placebo combination arm.

5 Oct 2009

ImThera Medical launches the aura6000 neurostimulation system for treating Obstructive Sleep Apnea

Today, at the American Academy of Otolaryngology-Head and Neck Surgery annual meeting, ImThera Medical, Inc. unveiled its new product, the aura6000™ neurostimulation system for the treatment of Obstructive Sleep Apnea (OSA).

5 Oct 2009

Positive results from Depomed's Phase 3 clinical trial of DM-1796 for postherpetic neuralgia

Depomed, Inc. today announced top-line results from a Phase 3 clinical trial demonstrating DM-1796 (also referred to as gabapentin ER) achieved a statistically significant reduction in pain associated with postherpetic neuralgia (PHN) versus placebo using the baseline observation carried forward (BOCF) method required by FDA.

5 Oct 2009

GSK reports positive Phase II results from trial evaluating GSK1838262 for post-herpetic neuralgia

GlaxoSmithKline and XenoPort, Inc. today announced top-line results from a Phase II clinical trial evaluating GSK1838262/XP13512 (gabapentin enacarbil) in adult patients with neuropathic pain associated with post-herpetic neuralgia (PHN) who have had a history of inadequate response to gabapentin doses of 1800 mg/day or higher.

5 Oct 2009

Surgeon Spotlight Series showcases interview with top orthopaedic surgeons

Allen Medical Systems, a Hill-Rom company, announces the second in its Surgeon Spotlight Series showcasing interviews with top orthopaedic surgeons. Carlos A. Guanche, M.D., managing partner at Southern California Orthopaedic Institute, is the featured surgeon and is recognized for his contributions in expanding the use of the Allen Intraoperative Arm Positioner for elbow fractures, scopes and clavicle repair procedures.

5 Oct 2009

Survey finds majority of Americans are at risk of heart disease due to their lifestyle factor

To help draw attention to National Child Health Day (today), the Preventive Cardiovascular Nurses Association (PCNA) has released findings from a new national consumer survey and launched a campaign to educate families about heart disease, the leading cause of death in the U.S.

5 Oct 2009

Autistic patients have underlying medical disorders that are amenable to treatment

The National Children's Health Survey published results from a 2007 telephone survey in Pediatrics today in which 78,000 households in the US were asked if their child (ages 2-17) was known to "currently have autism, Asperger's Disorder, pervasive development disorder, or other autism spectrum disorder." The survey showed that 1% of children (one in 100) now have the disorder. Previous estimates from the CDC had reported a prevalence rate of one in 150.

5 Oct 2009

Fifth SEEM anniversary meeting to be held in Belgrade

On 9 and 10 October the anniversary South Eastern European Meeting (SEEM) will be held in the Yugoslav Drama Theatre (Jugoslovensko Dramsko Pozoriste) in Belgrade (RS). Professor Michael Marberger (Vienna, AT), chairman of the Regional Office of the European Association of Urology: "For the 5th time the SEEM will provide a platform where new experimental and clinical work from the region is presented to an international audience".

5 Oct 2009

Prostate cancer and its influence on men's daily lives

Men who have prostate cancer often feel quite healthy, but the diagnosis still gives them a whole new outlook on life. Once they have learned to live with their cancer, they choose to focus on valuable relationships and appreciate the little things in life, shows a dissertation thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

5 Oct 2009

Registry to help patients in need of bone marrow transplants

Nearly 70 percent of patients needing a marrow transplant do not have a matching donor in their family, leaving minorities particularly vulnerable to finding a donor who can provide a perfect match of common tissue types, according to Be the Match®, a movement that engages the public to help patients in need of bone marrow or umbilical cord blood transplants.

5 Oct 2009

JCA-Mauvernay Award presented to Dr Toshikazu Ushijima for his research in oncology

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and the Japanese Cancer Association (JCA) presented 'The JCA-Mauvernay Award' to Dr Toshikazu Ushijima from the National Cancer Center Research Institute in Tokyo, for his outstanding and innovative research in basic science in the "epigenetic field for cancerization".

5 Oct 2009

National experts to address epilepsy disorder

The Epilepsy Foundation of Minnesota is partnering with Mayo Clinic to host a regional patient education conference called “Living with Seizures: Today & Tomorrow.” The regional conference will feature national experts in epilepsy, panel discussions and breakout sessions that include the following topics:

5 Oct 2009

Younger patients have increased risk for additional ACL surgery

Anterior cruciate ligament (ACL) injuries are one of the most common injuries to the knee. Each year thousands of patients undergo reconstructive surgery to repair these injuries. According to a new study published in the October 2009 issue of The Journal of Bone and Joint Surgery (JBJS), the number of patients undergoing ACL reconstruction is increasing substantially and women and younger patients are more likely to need subsequent knee surgery following the initial repair.

5 Oct 2009

Second annual Hispanic Radiothon to help children with cancer and other deadly diseases

Davidson Media Group (DMG) and St. Jude Children's Research Hospital(R) announce second annual Promesa y Esperanza (Promise and Hope) radiothon to be held October 8th and 9th.

5 Oct 2009

Medical Condition News

Alnara to announce Phase 3 study results of liprotamase for treating cystic fibrosis at the 23rd NACFC

Supportive housing program is cost-effective option for people with mental illness

VIVUS to present data on Qnexa at The Obesity Society meeting

FDA grants Impax tentative approval of ANDA for FLOMAX generic version

Positive results from Peregrine's Phase II bavituximab trial for non-small cell lung cancer

avVaa World Health Care Products launches Neuroskin Psoriasis Relief DRTV media test campaign

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

ImThera Medical launches the aura6000 neurostimulation system for treating Obstructive Sleep Apnea

Positive results from Depomed's Phase 3 clinical trial of DM-1796 for postherpetic neuralgia

GSK reports positive Phase II results from trial evaluating GSK1838262 for post-herpetic neuralgia

Surgeon Spotlight Series showcases interview with top orthopaedic surgeons

Survey finds majority of Americans are at risk of heart disease due to their lifestyle factor

Autistic patients have underlying medical disorders that are amenable to treatment

Fifth SEEM anniversary meeting to be held in Belgrade

Prostate cancer and its influence on men's daily lives

Registry to help patients in need of bone marrow transplants

JCA-Mauvernay Award presented to Dr Toshikazu Ushijima for his research in oncology

National experts to address epilepsy disorder

Younger patients have increased risk for additional ACL surgery

Second annual Hispanic Radiothon to help children with cancer and other deadly diseases

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News